Bibliografia

Burden of heart failure Care

Gheorghiade M et al. Am J Cardiol. 2005;96:11-17
Gheorghiade M et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes. Academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Failure Clin. 2013.9;285-290.
Marti NC et al.Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6:1095-1101
O’Connor CM et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduce left ventricular ejection fraction: results from efficacy of vasopressin antagonism in heart failure outcome stuy with tolvaptan (EVEREST) program. Am Heart J. 2010;159:841-849.e1.
Krumholz HM. Post-hospital Syndrome – An acquired, Transient Condition of Generalized Risk . NEJM. 2013;368;2
Marti NC et al. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure. Circ Heart Fail. 2013;6:1095-1101
Metra M et al. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation. 2010;122:1782-1785.
Gheorghiade M et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes. Academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Failure Clin. 2013:9;285-290
Yancy C et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240-e327.
Psotka MA, Teerlink JR. Strategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure. Heart Failure Clin. 2013;9:303-320.
Ryan J et al. Change in Readmissions and Follow-up Visits as Part of a Heart Failure Readmission Quality Improvement Initiative. Am J Med. 2013 Nov;126(11):989-994.e1. doi: 10.1016/j.amjmed.2013.06.027. Epub 2013 Sep 18.
Bradley EH et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(4):444-450.
Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J published 20 May 2016, 10.1093/eurheartj/ehw128
Habal MV et al. Association of Heart Rate at Hospital Discharge with Mortality and Hospitalizations in Patients with Heart Failure. Circ Heart Fail. 2014 Jan 1;7(1):12-20
Greene JC et al. EVEREST Trial Investigators. The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm: Insights From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) Trial. JACC Heart Failure. 2013;1(6):488-496.

Optimize Heart Failure Care

Schwartzmann P, Moreira HT, Mourilhe-Rocha R, Villacorta H, Souza-Neto JD, Sickler-Cruz T, Albuquerque D, Simoes MV [ESC]
Optimize Brazil – Analysis of a multidisciplinary approach in a multicenter Brazilian cohort to optimize heart failure treatment Eur J Heart Fail. 2017;19(Suppl.S1):73.

Lopatin Y, Grebennikova A, Sisakyan H, Hayrapetyan H, Dadashova G, Kurliandskaya A, Pagava Z, Kipiani Z, Berkinbayev S, Glezer M, Chesnikova A, Tarlovskaya E, Voronkov L, Tseluyko V, Abdullaev T [ESC]
Guidelines-recommended medications for heart failure in eight post-soviet countries: insights from the Optimize Heart Failure Care Program Eur J Heart Fail. 2017;19( Suppl.S1):224.

Saldarriaga C I, Gonzalez G, Navarrete S, Echeverria LE, Novoa M, Murillo N, Rivera A, Rodriguez MJ, Rolong B, Trout G, Martinez C, Arguello CV, Semanche L, Contreras E, Vanegas J [ESC]
Effect of ivabradine in the vulnerable phase: results from de Optimize Colombia Project Eur J Heart Fail. 2017;19(Suppl.S1):231.

Lopatin Y, Grebennikova A, Sisakian H, Hayrapetyan H, Pagava Z, Abdullaev T, Voronkov L, Tseluyko V, Chesnikova A, Glezer M, Koziolova N, Dadashova G, Berkinbaev S, Rakisheva A, Kurliandskaya A [ESC]
Beneficial effects of beta-blockers and ivabradine combination in patients hospitalized due to worsening of heart failure: findings from Optimize Heart Failure Care Program Eur J Heart Fail. 2017;19(Suppl.S1):288.

Sisakian H, Hayrapetyan H, Sahakyan L, Hovhanisyan M, Petrosyan H [ESC]
Chronic systolic heart failure rehospitalization rates study from OPTIMIZE HF Program: data from two centers Eur J Heart Fail. 2017;19(Suppl.S1):244.

Dadashova G. [ESC]
Characteristics, treatments, and outcomes of patients hospitalized for heart failure: a report from the OPTIMIZE-HF Registry (Azerbaijan) Eur J Heart Fail. 2017;19(Suppl.S1):404.

Kurlianskaya AK, Denicevich TL [ESC]
Management of patients with chronic heart failure and mid-range left ventricular ejection fraction Eur J Heart Fail. 2017;19(Suppl.S1):557.

Saldarriaga CI, Gonzalez G, Navarrete S, Echeverria LE, Novoa M, Murillo N, Rivera A, Rodriguez MJ, Rolong B, Trout G [Global Heart]
Optimization of heart failure treatment at hospital discharge: a 30-day follow-up study on behalf of the Roci Pilot Project Global Heart. 2016;11(Suppl. 2):e87.